The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The key unmet needs in a post-alloSCT newly diagnosed myeloma setting
In this video, Fredrik Schjesvold, MD, PhD, Oslo Myeloma Center, Oslo, Norway, suggests that the main unmet need in the post-allogeneic stem cell transplant (alloSCT) setting in newly diagnosed multiple myeloma (NDMM) is the lack of an effective maintenance strategy to prevent relapse in patients. Dr Schjesvold highlights that the approval of daratumumab plus lenalidomide maintenance in Europe is a step forward to improving outcomes for patients and also comments on the potential use of immunotherapeutic approaches as maintenance in the future. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
